Prostate cancer is a progressive, multistep disease which presents many stages for intervention. Microscopic cancer is found in the prostate beginning by age 30 in about 20% of men, and the incidence increases steadily so that by the time a man is 90 years old, he has almost a 100% chance of having cancer in his prostate. Independent, multiple foci of cancer are present in the majority of prostate specimens, and the incidence of premalignant lesions is even higher than that of cancer. Yet, despite the high incidence of microscopic cancer, only 8% of men in the US present with clinically significant disease during their lifetime. Furthermore, only 3% of men in the US die of prostate cancer. In no other human cancer is there such disparity between the high incidence of microscopic malignancy and the relatively low death rate. Thus, there are many windows of opportunity for control of prostate cancer. Evidence from diverse areas of study – epidemiologic, molecular, genetic, cellular, animal models, and clinical trials – suggests that vitamin D may be an effective preventive agent against prostate cancer.

1.
Berger U, Wilson P, McClelland RA, Colston K, Haussler MR, Pike JW, Coombes RC: Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab 1988;67:607–613.
2.
Schleicher G, Privette TH, Stumpf WE: Distribution of soltriol [1,25(OH)2-vitamin D3] binding sites in male sex organs of the mouse: An autoradiographic study. J Histochem Cytochem 1989;37:1083–1086.
3.
Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P: The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α,25-dihydroxyvitamin D3. Cancer Res 1992;52:515–520.
4.
Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1,25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952–1960.
5.
Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 1990;10:1307–1311.
6.
Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH, Orentreich N: Vitamin D and prostate cancer: A prediagnostic study with stored sera (see comments). Cancer Epidemiol Biomarkers Prev 1993;2:467–472.
7.
Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA, Willett WC: Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 1998;58:442–447.
8.
Zhao XY, Ly LH, Peehl DM, Feldman D: 1α,25-Dihydroxyvitamin D3 action in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 1997;138:3290–3298.
9.
Lucia MS, Anzano MA, Slayter MV, Anver MR, Green DM, Shrader MW, Logsdon DL, Driver CL, Brown CC, Peer CW, et al: Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate. Cancer Res 1995;55:5621–5627.
10.
Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR: 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. Urology 1995;46:365–369.
11.
Gross C, Peehl DM, Feldman D: Vitamin D and prostate cancer; in Feldman D, Glorieux FH, Pike JW (eds): Vitamin D. San Diego, Acadmic Press, 1997, pp 1125–1139.
12.
Xue L, Yang K, Newmark H, Lipkin M: Induced hyperproliferation in epithelial cells of mouse prostate by a Western-style diet. Carcinogenesis 1997;18:995–999.
13.
Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH: The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 1996;7:1563–1570.
14.
Gross S, Stamey T, Hancock S, Feldman D: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 1998;159:2035–2040.
15.
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA: Prediction of bone density from vitamin D receptor alleles (see comments). Nature 1994;367:284–287.
16.
Gross C, Eccleshall TR, Malloy PJ, Villa ML, Marcus R, Feldman D: The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women (see comments). J Bone Miner Res 1996;11:1850–1855.
17.
Harris SS, Eccleshall TR, Gross C, Dawson-Hughes B, Feldman D: The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J Bone Miner Res 1997;12:1043–1048.
18.
Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA: Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108–4110.
19.
Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor (see comments). J Natl Cancer Inst 1997;89:166–170.
20.
Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ: Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prev 1998;7:385–390.
21.
Brasitus TA, Siltrin MD: Chemoprevention and colon cancer by vitamin D3 and its metabolites/analogs; in Feldman D, Glorieux FH, Pike JW (eds): Vitamin D. San Diego, Academic Press, 1997, pp 1141–1154.
22.
Colston K: Vitamin D and breast cancer: Therapeutic potential of new vitamin D analogs; in Feldman D, Glorieux FH, Pike JW (eds): Vitamin D. San Diego, Academic Press, 1997, pp 1107–1123.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.